<DOC>
	<DOCNO>NCT02305628</DOCNO>
	<brief_summary>This phase IV , prospective , multicenter , observational study ( regulatory post-marketing surveillance ) approximately 600 patient receive Herceptin SC ( trastuzumab , subcutaneous administration ) per approve local labeling . Patients observation accord standard care Korea .</brief_summary>
	<brief_title>An Observational Study Herceptin SC Safety Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>All patient administer Herceptin SC locally approve indication All patient must provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>